Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of MK-1026 in relapsed or refractory B-cell hematologic malignancies
MOH_2021-04-18_009504Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of suvorexant in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Richter's syndrome (RS), mantle cell lymphoma (MCL) and 4 more (9 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability, Recommended phase 2 dose and 2 more. Started Jan 2021; status: recruiting.
02
Drugs
suvorexant
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Richter's syndrome (RS)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2021-04-18_009504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-18_009504.